TRβ Agonist Compositions for Fibrosis and Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis are limited in efficacy and irreversible, with a need for additional therapeutic approaches that can address both fibrosis and inflammation, as they often occur together.
Innovation Solution
Administering thyroid hormone receptor-β (TRβ) agonists to treat fibrosis and associated inflammation by targeting the TRβ pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current treatments (corticosteroids, immunosuppressants, biologics) are used to treat fibrosis and inflammation, then inflammation can be suppressed, but fibrosis progression continues and serious side effects occur
Solution Approach 1:
The patent converts the harmful effect of TGF-beta1 (which drives both fibrosis and inflammation) into a beneficial target for therapy. By developing antibodies that specifically block TGF-beta1's fibrotic effects while preserving its anti-inflammatory properties, the patent transforms a harmful driver into a controllable target, achieving fibrosis reversal without the side effects of conventional immunosuppressants
Solution Approach 2:
The patent changes the parameter of TGF-beta1 activity by using monoclonal antibodies to selectively modify its function. The antibodies alter TGF-beta1's binding characteristics and signaling pathways, changing its effect from unchecked fibrosis promotion to controlled activity, thereby resolving the contradiction between suppressing inflammation and preventing fibrosis
2Object-generated harmful factors
If conventional therapies are used to treat fibrosis, then fibrosis can be suppressed, but inflammation persists and quality of life deteriorates
Solution Approach 1:
The patent applies local quality by targeting specific functions of TGF-beta1 differently. The monoclonal antibodies are designed to selectively interfere with TGF-beta1's fibrotic signaling pathways while leaving its anti-inflammatory functions intact. This selective targeting allows simultaneous control of fibrosis and preservation of inflammation suppression, resolving the contradiction between suppressing fibrosis and maintaining inflammation control
3Object-affected harmful factors
If immunosuppressants and biologics are used to treat fibrosis and inflammation, then inflammation can be controlled, but serious side effects occur and quality of life is reduced
Solution Approach 1:
The patent extracts the harmful fibrotic activity from TGF-beta1's functional profile by using monoclonal antibodies to selectively block fibrotic signaling pathways. This extraction allows the preservation of TGF-beta1's beneficial anti-inflammatory properties while eliminating its harmful fibrotic effects, thereby controlling inflammation without the serious side effects associated with conventional immunosuppressants
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β–dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.